Clinical trials: Psoriatic Subjects
Psoriatic Arthritis
Study of Efficacy, Safety and Effect on Radiographic Progression of Brodalumab in Subjects With Psoriatic Arthritis
The primary objective of this study is to evaluate the efficacy of brodalumab, compared to placebo, in subjects with psoriatic arthritis.
- Trial name
- AMVISION-1 (NCT02029495)
- Testing
- 210 mg brodalumab, 140 mg brodalumab
- Where
- 152 sites in United States, Belgium and 15 more
- Volunteers
- 478 people
- Sponsor
- Bausch Health Americas, Inc.
Active Psoriatic Arthritis
Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2)
This is a randomized, double-blinded, placebo-controlled, Phase 3 study to evaluate the efficacy and safety of tildrakizumab compared to placebo in anti-TNF naïve subjects with active PsA .
- Trial name
- NCT04314531
- Testing
- TILD
- Where
- 49 sites in United States, Australia and 7 more
- Volunteers
- 296 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Psoriasis Vulgaris, Psoriatic Arthritis
A Phase 4 Clinical Study of Brodalumab
This study [4827-005 (post market)] is designed to evaluate the safety and efficacy of long-term exposure to brodalumab in subjects with plaque psoriasis (psoriasis vulgaris, psoriatic arthritis) who have completed Study 4827-003…
- Conditions
- Psoriasis Vulgaris, Psoriatic Arthritis, Pustular; Psoriasis, Palmaris Et Plantaris, Psoriatic Erythroderma
- Trial name
- NCT04183881
- Testing
- Brodalumab 210mg SC
- Where
- Japan
- Volunteers
- 138 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Psoriatic Arthritis
Protocol for H.P. Acthar Gel in Moderately to Severely Active Psoriatic Arthritis
Psoriatic arthritis is a heterogeneous chronic inflammatory disorder involving joints, tendon sheaths, entheses, and the axial skeleton as well as skin and nails. This is an open-label trial with H.P.
- Trial name
- NCT01939132
- Testing
- Open label H.P. Acthar Gel
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Fiechtner, Justus J., M.D., P.C.
Psoriatic Arthritis
Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
Psoriatic arthritis (PsA) is a long-term inflammatory disease that affects the joints and skin. The purpose of this study is to check how safe zasocitinib is, how well it is tolerated and how well it works in adults with PsA over…
- Trial name
- NCT07286058
- Testing
- Zasocitinib
- Where
- 78 sites in United States, Australia and 14 more
- Volunteers
- 1,182 people
- Sponsor
- Takeda
Moderate to Severe Plaque-type Psoriasis
Efficacy and Safety of Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque-type Psoriasis for up to 1 Year
This study will assess the safety and efficacy of secukinumab compared to placebo in patients that have moderate to severe, chronic, plaque-type psoriasis.
- Trial name
- ERASURE (NCT01365455)
- Testing
- secukinumab 150 mg
- Where
- 88 sites in United States, Argentina and 10 more
- Volunteers
- 738 people
- Sponsor
- Novartis Pharmaceuticals
Psoriatic Arthritis
Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis
The purpose of this study is to determine whether apremilast is safe and effective in the treatment of patients with psoriatic arthritis, specifically in improving signs and symptoms of psoriatic arthritis (tender and swollen…
- Trial name
- PALACE-1 (NCT01172938)
- Testing
- Apremilast 20mg, Apremilast 30mg
- Where
- 92 sites in United States, Australia and 11 more
- Volunteers
- 504 people
- Sponsor
- Amgen
Psoriatic Arthritis
Comparative Study to Evaluate the Pharmacokinetics of BAT2506 vs Simponi® in Healthy Subjects
It is a randomized, double-blinded, single-dose, 2-arm parallel, comparative study to evaluate the pharmacokinetics and safety of BAT2506 Injection vs Simponi in healthy chinese male subjects A total of 182 subjects are planned…
- Trial name
- NCT04152759
- Testing
- Drug: BAT2506 injection Other Names: Simponi(EU-licensed)
- Where
- China
- Volunteers
- 182 people, healthy volunteers welcome
- Sponsor
- Bio-Thera Solutions
Psoriatic Arthritis
Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis
The purpose of this study is to determine whether apremilast is safe and effective for treating patients with psoriatic arthritis.
- Trial name
- NCT01925768
- Testing
- Apremilast 30 mg
- Where
- 71 sites in United States, Australia and 8 more
- Volunteers
- 219 people
- Sponsor
- Amgen
Psoriatic Arthritis
Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Are Naive to Biologic DMARD Therapy
The primary objective of this study is to evaluate the effect of filgotinib compared to placebo as assessed by the American College of Rheumatology 20% improvement (ACR20) response in participants with active psoriatic arthritis…
- Trial name
- PENGUIN 1 (NCT04115748)
- Testing
- Filgotinib, Adalimumab
- Where
- 74 sites in United States, Australia and 11 more
- Volunteers
- 67 people
- Sponsor
- Gilead Sciences
Psoriasis
Safety, Tolerability And Efficacy Study Of Topical PF-06763809 In Subjects With Mild To Moderate Chronic Plaque Psoriasis
The study is a randomized, double blinded, vehicle and active comparator controlled, multiple dose study in subjects with chronic plaque psoriasis. The study will have approximately 15 completers.
- Trial name
- NCT03469336
- Testing
- PF-06763809, Vehicle, Calcipotriene/calcipotriol
- Where
- 2 sites in Germany
- Volunteers
- 18 people
- Sponsor
- Pfizer
Active Psoriatic Arthritis
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)
This is a multicenter Phase III, Randomized, Double-Blind, Single-Dose, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of tildrakizumab in Subjects with Active Psoriatic Arthritis I (INSPIRE 1)
- Trial name
- NCT04314544
- Testing
- TILD
- Where
- 97 sites in United States, Canada and 10 more
- Volunteers
- 508 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Psoriasis, Psoriatic Arthritis
Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) In Japanese Patients With Moderate-To-Severe Plaque-Type Psoriasis
This study will test the clinical effectiveness and safety of two orally administered doses of apremilast compared to placebo in Japanese patients with moderate-to-severe plaque-type psoriasis.
- Conditions
- Psoriasis, Psoriatic Arthritis, Psoriasis Arthropatica
- Trial name
- NCT01988103
- Testing
- Apremilast
- Where
- 56 sites in Japan
- Volunteers
- 254 people
- Sponsor
- Amgen
Psoriatic Subjects
To Evaluate the Efficacy and Safety of RSS0393 Ointment in Patients With Plaque Psoriasis Phase II Study
To evaluate the efficacy and safety of RSS0393 ointment in patients with plaque psoriasis Phase II study
- Trial name
- NCT06918743
- Testing
- RSS0393 ointment
- Volunteers
- 147 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.